RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $14
RBC Capital analyst Gregory Renza maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowers the price target from $15 to $14.
Nuvation Bio Q1 EPS $(0.10) Up From $(0.12) YoY
Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.10) per share. This is a 16.67 percent increase over losses of $(0.12) per share from the same period last year.
BMO Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $12
BMO Capital analyst Evan Seigerman maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowers the price target from $17 to $12.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 147 companies achieved new lows for the year.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.